EQS-News: Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities

Press Release // June 18, 2025
 

Ordinary Annual General Meeting of Formycon AG approves all proposed resolutions by large majorities

• Management provides detailed report on financial year 2024 and provides outlook for 2025
• Supervisory Board expands to six members; Klaus Röhrig re-elected
• Dr. Graham Keith Dixon elected as a new member of the Supervisory Board

Planegg-Martinsried, Germany – Formycon AG (FSE: FYB, “Formycon”) held its Annual General Meeting on 18 June 2025 as an in-person event in Munich. In its presentation, the Management Board provided shareholders with a detailed report on the company's development and answered all questions in the general debate.

In its report to the Annual General Meeting, the Management Board highlighted Formycon’s strong operational performance in the 2024 fiscal year and provided a detailed outlook for the ongoing year 2025. The company has successfully evolved in recent years from a purely development-focused organization into a commercially oriented biosimilar company with a steadily expanding and maturing product portfolio. Increasing revenues from global licensing and commercialization partnerships now provide a robust foundation for implementing the company’s growth strategy. The Management Board reaffirmed its commitment to maintaining this positive momentum, unlocking new market opportunities, and further expanding Formycon’s international presence.

The represented shareholders followed the proposals of the Management Board and Supervisory Board and approved all of the Executive Board’s proposed resolution resolutions with large majorities. Both the members of the Management Board and the Supervisory Board were given a formal approval of their actions with majorities of over 97 per cent in each case.

The resolution to expand the Supervisory Board from five to six members was passed to meet the growing requirements for the Board following the Company’s listing in the Prime Standard. Klaus Röhrig, Co-Chief Investment Officer of Active Ownership Capital S.à r.l. and Active Ownership Corporation S.à r.l., whose term of office as a member of the Supervisory Board ended automatically at the end of the Annual General Meeting on 18 June 2025, was re-elected as member of the Supervisory Board by a large majority. To further strengthen the Supervisory Board’s international focus and expertise, Dr. Graham Keith Dixon, Chief Executive Officer (CEO) of Estetra SRL, a subsidiary of Gedeon Richter Plc., was also elected to the expanded Supervisory Board by a large majority.

Wolfgang Essler, chief representative of the main shareholder ATHOS KG and Chairman of the Supervisory Board of Formycon AG, commented: “On behalf of the Supervisory Board of Formycon AG, I would like to congratulate Klaus on his re-election and Graham on his election. We look forward to their contributions and perspectives as we continue our close and constructive collaboration with the Formycon Management Board. The growing importance of biosimilars in global healthcare markets underscores Formycon’s strategic focus, positioning it as a leader in biosimilar development and delivering long-term value for patients and shareholders alike.”

Votes were cast for 67.06 percent of the share capital. The detailed voting results and further information on the 2025 Annual General Meeting can be found at Annual General Meeting - Formycon.

About Formycon:
Formycon AG (FSE: FYB) is a leading, independent developer of high-quality biosimilars, follow-on products of biopharmaceutical medicines. The company focuses on therapies in ophthalmology, immunology, immuno-oncology and other key disease areas, covering almost the entire value chain from technical development through clinical trials to approval by the regulatory authorities. For commercialization of its biosimilars, Formycon relies on strong, well-trusted and long-term partnerships worldwide. With FYB201/ranibizumab and FYB202/ustekinumab, Formycon already has two biosimilars on the market. Another biosimilar, FYB203/aflibercept, has been approved by the FDA, EMA, and MHRA. Four pipeline candidates are currently in development. With its biosimilars, Formycon is making an important contribution to providing as many patients as possible with access to highly effective and affordable medicines.

Formycon AG is headquartered in Munich, listed in the Prime Standard of the Frankfurt Stock Exchange: FYB / ISIN: DE000A1EWVY8 / WKN: A1EWVY and is part of the SDAX and TecDax selection indices. Further information can be found at: https://www.formycon.com/

About Biosimilars:
Since their introduction in the 1980s, biopharmaceutical drugs have revolutionized the treatment of serious and chronic diseases. By 2032, many of these drugs will lose their patent protection – including 45 blockbusters with an estimated total annual global turnover of more than 200 billion US dollars. Biosimilars are successor products to biopharmaceutical drugs for which market exclusivity has expired. They are approved in highly regulated markets such as the EU, the USA, Canada, Japan and Australia in accordance with strict regulatory procedures. Biosimilars create competition and thus give more patients access to biopharmaceutical therapies. At the same time, they reduce costs for healthcare systems. Global sales of biosimilars currently amount to around 21 billion US dollars. Analysts assume that sales could rise to over 74 billion US dollars by 2030.

Contact:
Sabrina Müller,
Director Investor Relations & Corporate Communications,
Formycon AG
Fraunhoferstr. 15
82152 Planegg-Martinsried
Germany

Tel.: +49 (0) 89 - 86 46 67 149
Fax: + 49 (0) 89 - 86 46 67 110

Sabrina.Mueller@formycon.com

Disclaimer:
This press release may contain forward-looking statements and information which are based on Formycon’s current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.